Try a new search

Format these results:

Searched for:

in-biosketch:yes

person:wangj59

Total Results:

67


Changes in serum IL8 levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small cell lung cancer patients [Meeting Abstract]

Sanmamed, M. F.; Perez-Gracia, J. L.; Fusco, J. P.; Onate, C.; Perez, G.; Alfaro, C.; Martin-Algarra, S.; Gonzalez, A.; Rodriguez-Ruiz, M. E.; Andueza, M. P.; Wang, J.; Bacchiocchi, A.; Halaban, R.; Kluger, H.; Sznol, M.; Melero, I.
ISI:000393913000143
ISSN: 0923-7534
CID: 4216672

Oxidative phosphorylation-dependent regulation of cancer cell apoptosis in response to anticancer agents

Yadav, N; Kumar, S; Marlowe, T; Chaudhary, A K; Kumar, R; Wang, J; O'Malley, J; Boland, P M; Jayanthi, S; Kumar, T K S; Yadava, N; Chandra, D
Cancer cells tend to develop resistance to various types of anticancer agents, whether they adopt similar or distinct mechanisms to evade cell death in response to a broad spectrum of cancer therapeutics is not fully defined. Current study concludes that DNA-damaging agents (etoposide and doxorubicin), ER stressor (thapsigargin), and histone deacetylase inhibitor (apicidin) target oxidative phosphorylation (OXPHOS) for apoptosis induction, whereas other anticancer agents including staurosporine, taxol, and sorafenib induce apoptosis in an OXPHOS-independent manner. DNA-damaging agents promoted mitochondrial biogenesis accompanied by increased accumulation of cellular and mitochondrial ROS, mitochondrial protein-folding machinery, and mitochondrial unfolded protein response. Induction of mitochondrial biogenesis occurred in a caspase activation-independent mechanism but was reduced by autophagy inhibition and p53-deficiency. Abrogation of complex-I blocked DNA-damage-induced caspase activation and apoptosis, whereas inhibition of complex-II or a combined deficiency of OXPHOS complexes I, III, IV, and V due to impaired mitochondrial protein synthesis did not modulate caspase activity. Mechanistic analysis revealed that inhibition of caspase activation in response to anticancer agents associates with decreased release of mitochondrial cytochrome c in complex-I-deficient cells compared with wild type (WT) cells. Gross OXPHOS deficiencies promoted increased release of apoptosis-inducing factor from mitochondria compared with WT or complex-I-deficient cells, suggesting that cells harboring defective OXPHOS trigger caspase-dependent as well as caspase-independent apoptosis in response to anticancer agents. Interestingly, DNA-damaging agent doxorubicin showed strong binding to mitochondria, which was disrupted by complex-I-deficiency but not by complex-II-deficiency. Thapsigargin-induced caspase activation was reduced upon abrogation of complex-I or gross OXPHOS deficiency whereas a reverse trend was observed with apicidin. Together, these finding provide a new strategy for differential mitochondrial targeting in cancer therapy.
PMCID:4670921
PMID: 26539916
ISSN: 2041-4889
CID: 5689202

Design and Implementation of the International Genetics and Translational Research in Transplantation Network

Keating, Brendan J; van Setten, Jessica; Jacobson, Pamala A; Holmes, Michael V; Verma, Shefali S; Chandrupatla, Hareesh R; Nair, Nikhil; Gao, Hui; Li, Yun R; Chang, Bao-Li; Wong, Chanel; Phillips, Randy; Cole, Brian S; Mukhtar, Eyas; Zhang, Weijia; Cao, Hongzhi; Mohebnasab, Maede; Hou, Cuiping; Lee, Takesha; Steel, Laura; Shaked, Oren; Garifallou, James; Miller, Michael B; Karczewski, Konrad J; Akdere, Abdullah; Gonzalez, Ana; Lloyd, Kelsey M; McGinn, Daniel; Michaud, Zach; Colasacco, Abigail; Lek, Monkol; Fu, Yao; Pawashe, Mayur; Guettouche, Toumy; Himes, Aubree; Perez, Leat; Guan, Weihua; Wu, Baolin; Schladt, David; Menon, Madhav; Zhang, Zhongyang; Tragante, Vinicius; de Jonge, Nicolaas; Otten, Henny G; de Weger, Roel A; van de Graaf, Ed A; Baan, Carla C; Manintveld, Olivier C; De Vlaminck, Iwijn; Piening, Brian D; Strehl, Calvin; Shaw, Mary; Snieder, Harold; Klintmalm, Goran B; O'Leary, Jacqueline G; Amaral, Sandra; Goldfarb, Samuel; Rand, Elizabeth; Rossano, Joseph W; Kohli, Utkarsh; Heeger, Peter; Stahl, Eli; Christie, Jason D; Fuentes, Maria Hernandez; Levine, John E; Aplenc, Richard; Schadt, Eric E; Stranger, Barbara E; Kluin, Jolanda; Potena, Luciano; Zuckermann, Andreas; Khush, Kiran; Alzahrani, Alhusain J; Al-Muhanna, Fahad A; Al-Ali, Amein K; Al-Ali, Rudaynah; Al-Rubaish, Abdullah M; Al-Mueilo, Samir; Byrne, Edna M; Miller, David; Alexander, Stephen I; Onengut-Gumuscu, Suna; Rich, Stephen S; Suthanthiran, Manikkam; Tedesco, Helio; Saw, Chee L; Ragoussis, Jiannis; Kfoury, Abdallah G; Horne, Benjamin; Carlquist, John; Gerstein, Mark B; Reindl-Schwaighofer, Roman; Oberbauer, Rainer; Wijmenga, Cisca; Palmer, Scott; Pereira, Alexandre C; Segovia, Javier; Alonso-Pulpon, Luis A; Comez-Bueno, Manuel; Vilches, Carlos; Jaramillo, Natalia; de Borst, Martin H; Naesens, Maarten; Hao, Ke; MacArthur, Daniel G; Balasubramanian, Suganthi; Conlon, Peter J; Lord, Graham M; Ritchie, Marylyn D; Snyder, Michael; Olthoff, Kim M; Moore, Jason H; Petersdorf, Effie W; Kamoun, Malek; Wang, Jun; Monos, Dimitri S; de Bakker, Paul I W; Hakonarson, Hakon; Murphy, Barbara; Lankree, Matthew B; Garcia-Pavia, Pablo; Oetting, William S; Birdwell, Kelly A; Bakker, Stephan J L; Israni, Ajay K; Shaked, Abraham; Asselbergs, Folkert W
BACKGROUND:Genetic association studies of transplantation outcomes have been hampered by small samples and highly complex multifactorial phenotypes, hindering investigations of the genetic architecture of a range of comorbidities which significantly impact graft and recipient life expectancy. We describe here the rationale and design of the International Genetics & Translational Research in Transplantation Network. The network comprises 22 studies to date, including 16494 transplant recipients and 11669 donors, of whom more than 5000 are of non-European ancestry, all of whom have existing genomewide genotype data sets. METHODS:We describe the rich genetic and phenotypic information available in this consortium comprising heart, kidney, liver, and lung transplant cohorts. RESULTS:We demonstrate significant power in International Genetics & Translational Research in Transplantation Network to detect main effect association signals across regions such as the MHC region as well as genomewide for transplant outcomes that span all solid organs, such as graft survival, acute rejection, new onset of diabetes after transplantation, and for delayed graft function in kidney only. CONCLUSIONS:This consortium is designed and statistically powered to deliver pioneering insights into the genetic architecture of transplant-related outcomes across a range of different solid-organ transplant studies. The study design allows a spectrum of analyses to be performed including recipient-only analyses, donor-recipient HLA mismatches with focus on loss-of-function variants and nonsynonymous single nucleotide polymorphisms.
PMCID:4623847
PMID: 26479416
ISSN: 1534-6080
CID: 5479282

S100A4 promotes liver fibrosis via activation of hepatic stellate cells

Chen, Lin; Li, Jie; Zhang, Jinhua; Dai, Chengliang; Liu, Xiaoman; Wang, Jun; Gao, Zhitao; Guo, Hongyan; Wang, Rui; Lu, Shichun; Wang, Fusheng; Zhang, Henghui; Chen, Hongsong; Fan, Xiaolong; Wang, Shengdian; Qin, Zhihai
BACKGROUND & AIMS/OBJECTIVE:S100A4 has been linked to the fibrosis of several organs due to its role as a fibroblast-specific marker. However, the role of S100A4 itself in the development of fibrosis has not been much investigated. Here, we determined whether S100A4 regulates liver fibrogenesis and examined its mechanism by focusing on the activation of hepatic stellate cells (HSCs). METHODS:S100A4 deficient mice were used to determine the role of S100A4 in liver fibrogenesis. The effect of S100A4 on HSC activation was estimated by using primary mouse HSCs and the human HSC cell line LX-2. Serum levels of S100A4 in cirrhotic patients were determined by ELISA. RESULTS:S100A4 was found to be secreted by a subpopulation of macrophages and to promote the development of liver fibrosis. It accumulated in the liver during the progression of liver fibrosis and activated HSCs in mice. In vitro studies demonstrated that S100A4 induced the overexpression of alpha-smooth muscle actin through c-Myb in HSCs. Both, the selective depletion of S100A4-expressing cells and knockdown of S100A4 in the liver by RNA interference, resulted in a reduction of liver fibrosis following injury. Importantly, increased S100A4 levels in both the liver tissue and serum correlated positively with liver fibrosis in humans. CONCLUSIONS:S100A4 promotes liver fibrosis by activating HSCs, which may represent a potential target for anti-fibrotic therapies.
PMID: 25111176
ISSN: 1600-0641
CID: 4154762

Advantage of Whole Exome Sequencing over Allele-Specific and Targeted Segment Sequencing in Detection of Novel TULP1 Mutation in Leber Congenital Amaurosis

Guo, Yiran; Prokudin, Ivan; Yu, Cong; Liang, Jinlong; Xie, Yi; Flaherty, Maree; Tian, Lifeng; Crofts, Stephanie; Wang, Fengxiang; Snyder, James; Donaldson, Craig; Abdel-Magid, Nada; Vazquez, Lyam; Keating, Brendan; Hakonarson, Hakon; Wang, Jun; Jamieson, Robyn V
BACKGROUND:Leber congenital amaurosis (LCA) is a severe form of retinal dystrophy with marked underlying genetic heterogeneity. Until recently, allele-specific assays and Sanger sequencing of targeted segments were the only available approaches for attempted genetic diagnosis in this condition. A broader next-generation sequencing (NGS) strategy, such as whole exome sequencing, provides an improved molecular genetic diagnostic capacity for patients with these conditions. MATERIALS AND METHODS/METHODS:In a child with LCA, an allele-specific assay analyzing 135 known LCA-causing variations, followed by targeted segment sequencing of 61 regions in 14 causative genes was performed. Subsequently, exome sequencing was undertaken in the proband, unaffected consanguineous parents and two unaffected siblings. Bioinformatic analysis used two independent pipelines, BWA-GATK and SOAP, followed by Annovar and SnpEff to annotate the variants. RESULTS:No disease-causing variants were found using the allele-specific or targeted segment Sanger sequencing assays. Analysis of variants in the exome sequence data revealed a novel homozygous nonsense mutation (c.1081C > T, p.Arg361*) in TULP1, a gene with roles in photoreceptor function where mutations were previously shown to cause LCA and retinitis pigmentosa. The identified homozygous variant was the top candidate using both bioinformatic pipelines. CONCLUSIONS:This study highlights the value of the broad sequencing strategy of exome sequencing for disease gene identification in LCA, over other existing methods. NGS is particularly beneficial in LCA where there are a large number of causative disease genes, few distinguishing clinical features for precise candidate disease gene selection, and few mutation hotspots in any of the known disease genes.
PMID: 24547928
ISSN: 1744-5094
CID: 5478112

An integrated epigenomic analysis for type 2 diabetes susceptibility loci in monozygotic twins

Yuan, Wei; Xia, Yudong; Bell, Christopher G; Yet, Idil; Ferreira, Teresa; Ward, Kirsten J; Gao, Fei; Loomis, A Katrina; Hyde, Craig L; Wu, Honglong; Lu, Hanlin; Liu, Yuan; Small, Kerrin S; Viñuela, Ana; Morris, Andrew P; Berdasco, María; Esteller, Manel; Brosnan, M Julia; Deloukas, Panos; McCarthy, Mark I; John, Sally L; Bell, Jordana T; Wang, Jun; Spector, Tim D
DNA methylation has a great potential for understanding the aetiology of common complex traits such as Type 2 diabetes (T2D). Here we perform genome-wide methylated DNA immunoprecipitation sequencing (MeDIP-seq) in whole-blood-derived DNA from 27 monozygotic twin pairs and follow up results with replication and integrated omics analyses. We identify predominately hypermethylated T2D-related differentially methylated regions (DMRs) and replicate the top signals in 42 unrelated T2D cases and 221 controls. The strongest signal is in the promoter of the MALT1 gene, involved in insulin and glycaemic pathways, and related to taurocholate levels in blood. Integrating the DNA methylome findings with T2D GWAS meta-analysis results reveals a strong enrichment for DMRs in T2D-susceptibility loci. We also detect signals specific to T2D-discordant twins in the GPR61 and PRKCB genes. These replicated T2D associations reflect both likely causal and consequential pathways of the disease. The analysis indicates how an integrated genomics and epigenomics approach, utilizing an MZ twin design, can provide pathogenic insights as well as potential drug targets and biomarkers for T2D and other complex traits.
PMCID:4284644
PMID: 25502755
ISSN: 2041-1723
CID: 5257542

Myeloid cells' evasion of melanoma immunity [Comment]

Wang, Jun; Chen, Lieping
An immune-suppressive role of myeloid-derived suppressor cells (MDSCs) in melanoma has long been speculated, whereas molecular mechanisms underlying this role are not well understood. Here, Chung and colleagues show that dendritic cell-associated, heparan sulfate proteoglycans-dependent integrin ligand (DC-HIL), a cell surface immune-modulatory molecule, is highly expressed on tumor-associated MDSCs. Genetic ablation or antibody blockade of DC-HIL delays the growth of transplantable B16 melanoma in syngeneic mice, which is accompanied by enhanced antitumor T-cell activities. These findings support a role for DC-HIL in immune evasion within the melanoma microenvironment.
PMID: 25318429
ISSN: 1523-1747
CID: 4154812

IVIG immunotherapy protects against synaptic dysfunction in Alzheimer's disease through complement anaphylatoxin C5a-mediated AMPA-CREB-C/EBP signaling pathway

Gong, Bing; Pan, Yong; Zhao, Wei; Knable, Lindsay; Vempati, Prashant; Begum, Shimul; Ho, Lap; Wang, Jun; Yemul, Shrishailam; Barnum, Scott; Bilski, Amanda; Gong, Ben Y; Pasinetti, Giulio M
BACKGROUND:Complement component C5-derived C5a locally generated in the brain has been shown to protect against glutamate-induced neuronal apoptosis and beta-amyloid (Aβ) toxicity, but the mechanism is not clear. In this study, we tested the hypothesis that C5a influences upstream signal transduction pathways associated with cAMP-response element-binding protein (CREB) activation, in which alterations of CREB levels are associated with cognitive deterioration in AD. METHODS:CREB signaling pathway, synaptic plasticity and cognitive function were studied in C5a receptor knockout mice (C5aR(-/-)), C5a over expressing mice (C5a/GFAP) and in Tg2576 mice, an AD mouse model. RESULTS:(1) Cognitive function is severely impaired in C5aR(-/-) mice, coincident with the down-regulated CREB/CEBP pathway in brain. (2) Either the application of recombinant-human-C5a (hrC5a) or exogenous expression of C5a in the brain of a mouse model (C5a/GFAP) enhances this pathway. (3) Application of hrC5a in brain slices from Tg2576 mice significantly improves deficits in long-term potentiation (LTP), while this effect is blocked by a specific AMPA receptor antagonist. (4) Searching for a pharmacological approach to locally mediate C5a responses in the brain, we found that low-dose human intravenous immunoglobulin (IVIG) treatment improves synaptic plasticity and cognitive function through C5a-mediated induction of the CREB/CEBP pathway, while the levels of Aβ in the brain are not significantly affected. CONCLUSION/CONCLUSIONS:This study for the first time provides novel evidence suggesting that C5a may beneficially influence cognitive function in AD through an up-regulation of AMPA-CREB signaling pathway. IVIG may systematically improve cognitive function in AD brain by passing Aβ toxicity.
PMID: 23911420
ISSN: 1872-9142
CID: 5791022

Role of standardized grape polyphenol preparation as a novel treatment to improve synaptic plasticity through attenuation of features of metabolic syndrome in a mouse model

Wang, Jun; Tang, Cheuk; Ferruzzi, Mario G; Gong, Bing; Song, Brian J; Janle, Elsa M; Chen, Tzu-Ying; Cooper, Bruce; Varghese, Merina; Cheng, Alice; Freire, Daniel; Bilski, Amanda; Roman, Jessica; Nguyen, Tuyen; Ho, Lap; Talcott, Stephen T; Simon, James E; Wu, Qingli; Pasinetti, Giulio M
SCOPE/METHODS:Metabolic syndrome has become an epidemic and poses tremendous burden on the health system. People with metabolic syndrome are more likely to experience cognitive decline. As obesity and sedentary lifestyles become more common, the development of early prevention strategies is critical. In this study, we explore the potential beneficial effects of a combinatory polyphenol preparation composed of grape seed extract, Concord purple grape juice extract, and resveratrol, referred to as standardized grape polyphenol preparation (SGP), on peripheral as well as brain dysfunction induced by metabolic syndrome. METHODS AND RESULTS/RESULTS:We found dietary fat content had minimal effect on absorption of metabolites of major polyphenols derived from SGP. Using a diet-induced animal model of metabolic syndrome (DIM), we found that brain functional connectivity and synaptic plasticity are compromised in the DIM mice. Treatment with SGP not only prevented peripheral metabolic abnormality but also improved brain synaptic plasticity. CONCLUSION/CONCLUSIONS:Our study demonstrated that SGP, comprised of multiple bioavailable and bioactive components targeting a wide range of metabolic syndrome related pathological features, provides greater global protection against peripheral and central nervous system dysfunctions and can be potentially developed as a novel prevention/treatment for improving brain connectivity and synaptic plasticity important for learning and memory.
PMCID:3855562
PMID: 23963661
ISSN: 1613-4133
CID: 5791032

Unintended effects of cardiovascular drugs on the pathogenesis of Alzheimer's disease

Wang, Jun; Zhao, Zhong; Lin, Emi; Zhao, Wei; Qian, Xianjuan; Freire, Daniel; Bilski, Amanda E; Cheng, Alice; Vempati, Prashant; Ho, Lap; Ono, Kenjiro; Yamada, Masahito; Pasinetti, Giulio M
Alzheimer's disease (AD) is rapidly becoming one of the leading causes of disability and mortality in the elderly. As life-expectancy increases, an increasing number of people will rely on modern medicines to treat age-associated disorders. Among these medications, some might benefit, while others might exacerbate, the pathogenesis of AD. We screened 1,600 FDA approved drugs for β-amyloid (Aβ)-modifying activity and identified drugs that can potentially influence amyloid precursor protein processing. In this study, we focused on cardiovascular drugs and demonstrated that some hypertensive medication can differentially modulate Aβ, both in vitro and in vivo. Our study suggests that some commonly prescribed drugs might exert unintended effects and modulate AD and provides the basis for continuing investigation of the role of individual drugs on a case-by-case basis. This line of investigation will lead to the identification of common medications that are potentially beneficial or detrimental to AD as a reference for physicians to consider when prescribing the most appropriate drugs for their patients, particularly for treating chronic disorders among the growing geriatric population.
PMCID:3675203
PMID: 23762322
ISSN: 1932-6203
CID: 5791012